150 related articles for article (PubMed ID: 32499195)
21. What impact does 'conventional' economic evaluation have on patient access to new orphan medicines? A comparative study of their reimbursement in Australia (2005-2012).
Wonder M; Chin G
Expert Rev Pharmacoecon Outcomes Res; 2015; 15(5):843-50. PubMed ID: 25938794
[TBL] [Abstract][Full Text] [Related]
22. Patient Access to Medicines for Rare Diseases in European Countries.
Detiček A; Locatelli I; Kos M
Value Health; 2018 May; 21(5):553-560. PubMed ID: 29753352
[TBL] [Abstract][Full Text] [Related]
23. Drugs for rare diseases: mixed assessment in Europe.
Prescrire Int; 2007 Feb; 16(87):36-42. PubMed ID: 17323539
[TBL] [Abstract][Full Text] [Related]
24. Rationing of drugs for rare diseases.
Hughes D
Pharmacoeconomics; 2006; 24(4):315-6. PubMed ID: 16605277
[No Abstract] [Full Text] [Related]
25. Review and comparison of clinical evidence submitted to support European Medicines Agency market authorization of orphan-designated oncological treatments.
Winstone J; Chadda S; Ralston S; Sajosi P
Orphanet J Rare Dis; 2015 Oct; 10():139. PubMed ID: 26511061
[TBL] [Abstract][Full Text] [Related]
26. The US Orphan Drug Act: rare disease research stimulator or commercial opportunity?
Wellman-Labadie O; Zhou Y
Health Policy; 2010 May; 95(2-3):216-28. PubMed ID: 20036435
[TBL] [Abstract][Full Text] [Related]
27. The challenges of orphan drugs and orphan diseases: real and imagined.
Hudson I; Breckenridge A
Clin Pharmacol Ther; 2012 Aug; 92(2):151-3. PubMed ID: 22814659
[TBL] [Abstract][Full Text] [Related]
28. For-profit clinical trials in developing countries--those troublesome patient benefits.
Schuklenk U
Am J Bioeth; 2010 Jun; 10(6):52-4. PubMed ID: 20526975
[No Abstract] [Full Text] [Related]
29. Rare essentials: drugs for rare diseases as essential medicines.
Stolk P; Willemen MJ; Leufkens HG
Bull World Health Organ; 2006 Sep; 84(9):745-51. PubMed ID: 17128345
[TBL] [Abstract][Full Text] [Related]
30. A cross-national comparative study of orphan drug policies in the United States, the European Union, and Japan: towards a made-in-China orphan drug policy.
Liu BC; He L; He G; He Y
J Public Health Policy; 2010 Dec; 31(4):407-20; discussion 420-1. PubMed ID: 21119648
[TBL] [Abstract][Full Text] [Related]
31. The European rare diseases therapeutic initiative.
Fischer A; Borensztein P; Roussel C
PLoS Med; 2005 Sep; 2(9):e243. PubMed ID: 16104832
[TBL] [Abstract][Full Text] [Related]
32. Orphanage at the FDA.
Chen E
J Cardiovasc Transl Res; 2012 Oct; 5(5):735-6. PubMed ID: 21080134
[No Abstract] [Full Text] [Related]
33. Evaluating and Valuing Drugs for Rare Conditions: No Easy Answers.
Ollendorf DA; Chapman RH; Pearson SD
Value Health; 2018 May; 21(5):547-552. PubMed ID: 29753351
[TBL] [Abstract][Full Text] [Related]
34. Orphan drugs: expensive yet necessary.
Hyry HI; Roos JC; Cox TM
QJM; 2015 Apr; 108(4):269-72. PubMed ID: 25434052
[TBL] [Abstract][Full Text] [Related]
35. Reimbursement of Drugs for Rare Diseases through the Public Healthcare System in Canada: Where Are We Now?
Menon D; Clark D; Stafinski T
Healthc Policy; 2015 Aug; 11(1):15-32. PubMed ID: 26571466
[TBL] [Abstract][Full Text] [Related]
36. Competing for public funding of medicines to treat rare disorders in New Zealand.
Crausaz S
Bull World Health Organ; 2015 Feb; 93(2):67. PubMed ID: 25883396
[No Abstract] [Full Text] [Related]
37. Access to orphan drugs in western Europe: can more systematic policymaking really help to avoid different decisions about the same drug?
Kanters TA; Hakkaart L; Rutten-van Mölken MP; Redekop WK
Expert Rev Pharmacoecon Outcomes Res; 2015; 15(4):557-9. PubMed ID: 25973903
[TBL] [Abstract][Full Text] [Related]
38. Crowdfunding for Personalized Medicine Research.
Fumagalli DC; Gouw AM
Yale J Biol Med; 2015 Dec; 88(4):413-4. PubMed ID: 26604866
[TBL] [Abstract][Full Text] [Related]
39. [The pharmacist, rare diseases and orphan medicines].
Nagore Induráin C; Lacalle E; Arteche L
An Sist Sanit Navar; 2008; 31 Suppl 2():127-43. PubMed ID: 18953376
[TBL] [Abstract][Full Text] [Related]
40. Quantifying emerging drugs for very rare conditions.
Miles KA; Packer C; Stevens A
QJM; 2007 May; 100(5):291-5. PubMed ID: 17456610
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
